Nanostructured immunosensing system for label-free impedimetric detection of multiple breast cancer biomarkers (CEA and HER2) using CoMoO4@PANI-PPy Nanocomposite

Breast cancer patients often exhibit positive expression of selective tumor biomarkers including the carcinoembryonic antigen (CEA), and human epidermal growth factor receptor 2 (HER2). These potential protein biomarkers are highly crucial for the selective and early tumor diagnosis. In this study, disposable dual impedimetric immunosensing systems were constructed using the cobalt molybdate (CoMoO 4 ) and polyaniline/polypyrrole (PANI-PPy) nanocomposite, for the rapid quantification of CEA and HER2 concentration levels. The designed sensing probes were fabricated by chemically conjugating two-targeting antibodies (anti-CEA and anti-HER2) on the nanostructured electrode surfaces modified with (AuNPs/CoMoO 4 @PANI-PPy). These successful chemical antibody immobilizations were enabled by the use of 4-aminothiophenol (4-ATP) as a cross-linking agent. The impedimetric immunosensing assay was fully optimized by screening of nanomaterials, determining the optimal ratio of the nanocomposite, adjusting the time of self-assembled monolayer (SAM) formation, and identifying the degree of cross-reactivity with potential non-targeting molecules. Accordingly, the biosensors demonstrated distinguished linear dynamic ranges of 1.0 fg/mL to 100 ng/mL for the CEA and 25 fg/mL to 100 ng/mL for the HER2, with detection limits of 8.2 fg/mL and 4.9 fg/mL for CEA and HER2, respectively. The immunesensor's reproducibility and stability were studied, showing minimal variation in charge transfer resistance (RSD = 1.33%, n = 5) and maintaining 82.5% functionality after four weeks of storage at 4 °C. These findings highlighted the potential use of these biosensor chips for clinical applications in early breast cancer detection and rapid diagnosis. • Portable, Disposable Biosensor for Label-Free Detection of Breast Cancer Biomarkers (CEA, Her2). • Synthesis and Immunosensing Applications of CoMoO4 Nanostructures for Cancer Detection. • Cost-effective, user-friendly system for early breast cancer diagnosis.

Authors

Institutions

Publication Details

Journal
Biosensors and Bioelectronics X
Published
2025-02-20
DOI
https://doi.org/10.1016/j.biosx.2025.100596
Citations
4
Primary Topic
Advanced biosensing and bioanalysis techniques
Type
article
Field-Weighted Citation Impact
3.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nanostructured immunosensing system for label-free impedimetric detection of multiple breast cancer biomarkers (CEA and HER2) using CoMoO4@PANI-PPy Nanocomposite

Rabeay Y. A. Hassan, Omar Ramadan
4 citations
Biosensors and Bioelectronics X
Advanced biosensing and bioanalysis techniques
3.22
article

Nanostructured immunosensing system for label-free impedimetric detection of multiple breast cancer biomarkers (CEA and HER2) using CoMoO4@PANI-PPy Nanocomposite

Rabeay Y. A. Hassan, Omar Ramadan
article en
4 citations

Abstract

Breast cancer patients often exhibit positive expression of selective tumor biomarkers including the carcinoembryonic antigen (CEA), and human epidermal growth factor receptor 2 (HER2). These potential protein biomarkers are highly crucial for the selective and early tumor diagnosis. In this study, disposable dual impedimetric immunosensing systems were constructed using the cobalt molybdate (CoMoO 4 ) and polyaniline/polypyrrole (PANI-PPy) nanocomposite, for the rapid quantification of CEA and HER2 concentration levels. The designed sensing probes were fabricated by chemically conjugating two-targeting antibodies (anti-CEA and anti-HER2) on the nanostructured electrode surfaces modified with (AuNPs/CoMoO 4 @PANI-PPy). These successful chemical antibody immobilizations were enabled by the use of 4-aminothiophenol (4-ATP) as a cross-linking agent. The impedimetric immunosensing assay was fully optimized by screening of nanomaterials, determining the optimal ratio of the nanocomposite, adjusting the time of self-assembled monolayer (SAM) formation, and identifying the degree of cross-reactivity with potential non-targeting molecules. Accordingly, the biosensors demonstrated distinguished linear dynamic ranges of 1.0 fg/mL to 100 ng/mL for the CEA and 25 fg/mL to 100 ng/mL for the HER2, with detection limits of 8.2 fg/mL and 4.9 fg/mL for CEA and HER2, respectively. The immunesensor's reproducibility and stability were studied, showing minimal variation in charge transfer resistance (RSD = 1.33%, n = 5) and maintaining 82.5% functionality after four weeks of storage at 4 °C. These findings highlighted the potential use of these biosensor chips for clinical applications in early breast cancer detection and rapid diagnosis. • Portable, Disposable Biosensor for Label-Free Detection of Breast Cancer Biomarkers (CEA, Her2). • Synthesis and Immunosensing Applications of CoMoO4 Nanostructures for Cancer Detection. • Cost-effective, user-friendly system for early breast cancer diagnosis.

Biosensors and Bioelectronics XVol. 23
Zewail City of Science and Technology (EG)
Science and Technology Development Fund
Good health and well-being
Openalex Percentile: Top 9%
Advanced biosensing and bioanalysis techniques
3.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.